Tenderwize
Zurück zur Suche

Non-exclusive rebate agreement for Ganirelix

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Jun 27, 2028 · 672 days left·Open·Supplies·Framework
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The structured data says first-start submissions for 01.09.2026 had to be received by 28.07.2026, while the XML notice...

Electronic submission is explicitly not allowed, so incorrect submission channel could invalidate participation.

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2028
  • Supply-related rebate agreement for pharmaceutical products containing Ganirelix (ATC H01CC01).
  • Open-house model with non-exclusive access for all interested and eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is a German open-house framework-style notice for a non-exclusive rebate agreement on Ganirelix (ATC H01CC01) for AOK Niedersachsen. The contract can start from 01.09.2026 and runs until 31.08.2028, with monthly entry possible during the term. No contract value is stated. Electronic submission is not allowed; documents must be requested and submitted by the address in the contract documents. The notice explicitly says it is not a public contract award in the sense of procurement law and that all interested, eligible pharmaceutical companies may join under uniform conditions.

Risiken

The structured data says first-start submissions for 01.09.2026 had to be received by 28.07.2026, while the XML notice...

Electronic submission is explicitly not allowed, so incorrect submission channel could invalidate participation.

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4 Abs. 18 AMG, or a consortium of pharmaceutical companies, for the offered medicines.
  • The company must be established in Germany, another EU Member State, or another EEA Contracting State for placing medicines on the market under the AMG.
  • Local representatives may participate only if they themselves qualify as pharmaceutical companies for the offered medicines.

Auftraggeber

Lose (1)

LOT-0000

Non-exclusive rebate agreement for Ganirelix

Single lot covering a non-exclusive open-house rebate agreement for medicinal products containing Ganirelix (ATC H01CC01). The buyer states that all interested pharmaceutical companies may join under uniform conditions, without selection decision or individual negotiations. The agreement is intended as a bridge until exclusive rebate contracts replace it. Contract term is up to 24 months, with entry possible on the first day of each month during the term. The lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE929, Germany

Dauer

Aug 2026 - Aug 2028

Kategorie

Pharmaceutical products

Frist

Expired Jul 28, 2026

Vergabedetails

Veröffentlichungsdatum
05 Jul 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
464687-2026

Ähnliche Ausschreibungen